SCHEMBL121801

SCHEMBL121801

Fc1cccc(F)c1CBr

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.43
KDM4E B2RXH2 4/20 0.41
GAA P10253 1/20 0.40
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
TSHR P16473 2/20 0.35
POLB P06746 1/20 0.35
NPC1 O15118 1/20 0.35
NFKB1 P19838 1/20 0.35
RAB9A P51151 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
TRPA1 O75762 1/20 0.35
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
HTT P42858 2/20 0.34
BACE1 P56817 1/20 0.34
DAO P14920 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029574 0.97 TAAR1 (0.41) TAAR1KDM4EGAAALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL29184016 0.97 TAAR1 (0.41) TAAR1KDM4EGAAALDH1A1SMN1; SMN2
Acetonitrile SCHEMBL16963780 0.86 KDM4E (0.38) TAAR1KDM4EGAAALDH1A1SMN1; SMN2
SCHEMBL4243083 0.85 EED (0.41) TAAR1KDM4EGAAALDH1A1SMN1; SMN2
SCHEMBL3304485 0.85 TAAR1 (0.38) TAAR1KDM4EGAAALDH1A1SMN1; SMN2
SCHEMBL29386736 0.85 EED (0.41) TAAR1KDM4EGAAALDH1A1SMN1; SMN2
SCHEMBL18984003 0.84 GABRA1 (0.46) TAAR1KDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL7997992 0.83 TAAR1 (0.41) TAAR1KDM4EGAAALDH1A1SMN1; SMN2
SCHEMBL15071663 0.83 ACHE (0.48) TAAR1KDM4EGAAALDH1A1SMN1; SMN2
SCHEMBL19443767 0.83 TAAR1 (0.36) TAAR1KDM4EGAAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634195-A1 PROCESS FOR THE PREPARATION OF RELUGOLIX Medichem, S.A. (ES) 2025-10-22 EP claimed
CN-119546611-A Preparation process and intermediate of rui Lu Geli 台湾神隆股份有限公司 2025-02-28 CN claimed
CN-119465288-A Anion exchange membrane, preparation method and application thereof, and electrolysis device 氢和元泰(常州)新材料科技有限公司 2025-02-18 CN claimed
WO-2024126674-A1 PROCESS FOR THE PREPARATION OF RELUGOLIX MEDICHEM, S.A. (ES) 2024-06-20 WO claimed
CN-117820161-A Synthesis method of Lu Fei amide intermediate 2-azidomethyl-1, 3-difluorobenzene 万特制药(海南)有限公司 2024-04-05 CN claimed
US-20230357267-A1 PROCESS FOR PREPARING RELUGOLIX AND INTERMEDIATES THEREOF SCINOPHARM TAIWAN, LTD. (TW) 2023-11-09 US claimed
WO-2023214935-A1 PROCESS FOR PREPARING RELUGOLIX AND INTERMEDIATES THEREOF SCINOPHARM TAIWAN, LTD. (TW) 2023-11-09 WO claimed
CN-112473396-B Anion exchange membrane material for diffusion dialysis acid recovery and preparation method thereof 西安建筑科技大学 2022-06-24 CN claimed
WO-2021047572-A1 GSK-3β/CHE DOUBLE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 中国药科大学 2021-03-18 WO claimed
CN-112473396-A Anion exchange membrane material for diffusion dialysis acid recovery and preparation method thereof 西安建筑科技大学 2021-03-12 CN claimed
CN-107089913-B 2-substituted methyl rupestonic acid derivative and preparation method and application thereof 中国科学院新疆理化技术研究所 2020-10-09 CN claimed
US-20170348258-A1 3-Amino Benzamide Derivative Serving As B-Lactam Auxiliary Antibiotic, Preparation Method and Use Thereof THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2017-12-07 US claimed
CN-104245692-B Industrial process for the preparation of high purity methzolin 牧牛研究所株式会社 2016-08-24 CN claimed
CN-105461585-A 3-aminobenzamide derivative as beta-lactam auxiliary antibiotic, preparation method and application UNIV HONG KONG POLYTECHNIC 2016-04-06 CN claimed
CN-104245692-A Industrial process for the preparation of high purity methzolin MOGHU RES CT LTD 2014-12-24 CN claimed
CN-103539750-A Synthesis process of rufinamide XUHE TIANJIN MEDICINE SCIENCE & TECHNOLOGY CO LTD 2014-01-29 CN claimed
CN-122080069-A Phospholipid compounds and uses thereof 2026-05-26 CN disclosed
US-12606564-B2 Adenosine receptor antagonist compounds ILDONG PHARMACEUTICAL CO., LTD. (KR) 2026-04-21 US disclosed
US-4695579-A Antifungal 2-azolylmethyl-3-difluorobenzyloxy-2,3-dihydrofluoro-benzo(B) thiophens SCHERING CORPORATION (US) 1987-09-22 US disclosed
EP-0185381-A2 2-Azolylmethyl-3-difluorobenzyloxy-2,3-dihydrofluorobenzo(b)thiophenes, process for their preparation and compositions containing them SCHERING CORPORATION (US) 1986-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348258-A1 3-Amino Benzamide Derivative Serving As B-Lactam Auxiliary Antibiotic, Preparation Method and Use Thereof BCAT2, SBDS, BCAT1 TAAR1 4348/4885KDM4E 1472/4885GAA 679/4885
US-12606564-B2 Adenosine receptor antagonist compounds ADORA2A, ADORA1, ADORA2B TAAR1 88/4885KDM4E 4084/4885GAA 3007/4885
US-20230357267-A1 PROCESS FOR PREPARING RELUGOLIX AND INTERMEDIATES THEREOF PRMT8, PRMT7, PRMT1 TAAR1 1061/4885KDM4E 26/4885GAA 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.